InvestorsHub Logo

H2R

Followers 42
Posts 2159
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Monday, 08/28/2017 7:03:09 PM

Monday, August 28, 2017 7:03:09 PM

Post# of 1190
JM Cuillerot, Aug. 31, at http://www.immuno-oncologysummit.com/Personalized-Cancer-Vaccines/


5:00 Autosynvax™ (ASV™), a Personalized Second Generation Vaccine Platform
Jean-Marie Cuillerot, M.D., CMO, Agenus
AutoSynVax™ (ASV™) vaccines contain patient-specific peptides with defined immunogenic epitopes resulting from specific mutations within a patient’s tumor, deduced using a proprietary algorithm, complexed with a recombinant HSP molecule (HSC70) and delivered with a saponin-based adjuvant. Preclinical studies demonstrate that heat shock protein-driven presentation of synthetic tumor neo-peptides evokes an anti-tumor immune response as well as lasting immune memory in murine cancer models.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AGEN News